How GLP‑1 receptor agonists affect unhealthy organ fat in people with chronic kidney disease
Official title: Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease
Run by Cardenal Herrera University · NCT07309094 · Data updated 2026-11-12
This observational project will test whether taking GLP‑1 receptor agonist medicines changes harmful fat around organs and related inflammation in adults with chronic kidney disease who also have obesity or type 2 diabetes.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 90 Years |
| Sex | All |
| Enrollment | 250 (estimated) |
| Sponsor | Cardenal Herrera University Academic / other |
| Locations | 1 site (Valencia, Valencia) |
| Status | Recruiting |
| Started | September 15, 2023 |
| Main results expected | July 31, 2027 |
| Study ends | December 31, 2028 |
| Registry record updated | December 30, 2025 |
| Trial ID | NCT07309094 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults aged 18 or older with chronic kidney disease stages G1–G4 (not on dialysis) who have uncontrolled type 2 diabetes, obesity, and/or cardiovascular disease and who can give informed consent are appropriate candidates.
✕Probably not a fit
People with end‑stage CKD (stage G5) or candidates for dialysis, pregnant individuals, or those with neuropsychiatric conditions preventing informed consent are unlikely to benefit from participation.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is an observational cohort study that follows adults with CKD stages G1–G4, comparing those treated with GLP‑1 receptor agonists to those not receiving these drugs while recording other glucose‑lowering therapies. Investigators will use imaging (CT/MRI), bioimpedance, morphometric measures, and blood biomarkers to quantify perivisceral adipose tissue, radiodensity, and pro‑inflammatory adipokines alongside kidney function measures. The study documents real‑world use of GLP‑1RAs, SGLT2 inhibitors, tirzepatide and other medications rather than assigning treatments. Data will be analyzed to link changes in adipose tissue characteristics with biochemical markers and clinical measures of kidney and cardiovascular risk.
Why it matters
Potential benefit: If successful, the findings could show that GLP‑1RAs reduce harmful periorgan fat and inflammation, which might help slow CKD progression and lower cardiovascular risk.
How similar studies have gone: Previous randomized and observational studies have shown renal and cardiovascular benefits of GLP‑1RAs in people with type 2 diabetes and obesity, but direct, detailed links between GLP‑1RA use and improvements in perivisceral adiposopathy remain less well established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * \> or = 18 years of age * diagnosed with CKD in stages G1, G2, G3a, G3b, and G4, not candidate for dialysis * had uncontrolled T2DM, CVDs and/or obesity * willing to participate in the study and sign informed consent Exclusion Criteria: * Age \<18 years * pregnancy * CKD in stage G5 or G4 candidate for dialysis * neuropsychiatric diseases preventing the patient from understanding the benefits/risks associated with the project * refusal to participate and/or consent revocation were considered as exclusion criteria
Where it's running
-
Vithas Valencia Consuelo
Valencia, Valencia, Spain Recruiting
Study contacts
- Principal investigator: Luis D'Marco, MD, PhD — Cardenal Herrera University
- Study coordinator: Ana Checa-Ros, MD, PhD
- Email: ana.checaros@uchceu.es
- Phone: +34 961369000
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Whole-Body Vibration Training in Women With Obesity With and Without Type 2 Diabetes
This study tests whether eight weeks of supervised whole-body vibration training changes ankle muscle activity and walking performance in women with obesity, comparing those with and without type 2 diabetes.
-
EloraTZP for weight loss in adults with overweight/obesity and type 2 diabetes
This trial tests whether a coformulation of eloralintide and tirzepatide helps people with obesity or overweight and type 2 diabetes lose weight compared with tirzepatide alone.
-
Clazakizumab for adults with high hsCRP at risk for a heart event
This study tests whether clazakizumab can lower inflammation and reduce cardiovascular risk in adults with high hsCRP and existing risk factors.
-
AI-assisted lifestyle plan vs. tirzepatide for obesity with newly diagnosed type 2 diabetes
This study tests whether an AI-guided lifestyle program can help overweight adults with newly diagnosed type 2 diabetes lose more weight and improve blood sugar control compared with tirzepatide or standard lifestyle care.
-
Long-term test of maridebart cafraglutide for obesity and type 2 diabetes
This extension study tests whether maridebart cafraglutide remains effective and safe for people with obesity and type 2 diabetes who previously completed a parent trial.
-
Tirzepatide in real-world Paraguay for obesity and type 2 diabetes
This study tests tirzepatide in adults in Paraguay to see how it works for weight loss and blood sugar control in everyday clinical practice.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.